Blog

AI in Pharma: How AI Drug Development in Europe (2025-2026) Can Reduce Timelines and Unlock Major Cost Savings

13 October, 2025

#article

AI in pharma is no longer a proof-of-concept - it’s becoming a core engine of AI drug development in Europe. Evidence points to reduced timelines and tangible cost savings across discovery and clinical execution. By shifting work in silico, teams filter candidates earlier, accelerate clinical trial design and streamline regulatory writing with generative AI.

In practice, smarter site selection, faster patient enrollment and risk-based monitoring compress cycle time, while EU-ready data pipelines address EHR interoperability and audit needs. The result is measurable clinical trial acceleration without sacrificing rigor: quicker protocols and CSRs, cleaner data and fewer deviations - supported by GxP validation and production-grade MLOps in pharma.

For European companies balancing innovation with compliance, the question has shifted from “if” to “how fast,” and how to scale responsibly across member states while capturing ROI.

From Pilots to Scale: Why AI in Pharma Matters for Europe in 2025–2026

A few years ago, analysts were already documenting AI across seven stages of development - from discovery to screening and optimisation - and projecting dramatic reductions in time and cost.

“AI could cut drug development timelines and save pharma companies up to $54 billion in R&D costs each year.”¹

What once sounded like blue-sky thinking now reads like a roadmap many companies are following. The market for AI/ML in discovery and development shows sustained double-digit growth, and regulators are leaning in: submissions that reference AI are rising, and fresh guidance is clarifying how to use AI to support regulatory decision-making for drugs and biologics. This maturing context reduces uncertainty for sponsors and sites and encourages investments in data pipelines, validation practices and governance that make AI results repeatable and auditable across Europe.

AI Drug Discovery & Preclinical Development in Europe: In-Silico Triage to Cut 1-2 Years

In discovery and preclinical work, AI prioritises compounds and predicts efficacy and toxicity, cutting low-probability wet-lab experiments. Reviews suggest the traditional three-to-six-year discovery window can be shortened by one to two years through in-silico screening and sharper triage³. Because discovery can account for roughly a third of the total cost to bring a drug to market, even modest improvements in hit quality translate into hundreds of millions in avoided spend - without sacrificing scientific rigour.

In practice, teams blend literature mining and NLP with omics and imaging data, then use active-learning loops and automated synthesis to accelerate design-make-test cycles. As one 2020 report put it,

“The increasing use of AI in the pharmaceutical industry will not only reduce costs, but enable more effective drugs to be created more quickly, boosting medical innovations and leading to a healthier world.”¹

Clinical Trial Acceleration: Site Selection, Patient Enrollment and Remote Monitoring

The centre of gravity for value is clinical execution. Across live programmes, sponsors are reporting double-digit reductions in cycle time, with particularly large gains in patient monitoring, enrolment assessments and the assembly of regulatory documentation.

As Ken Getz, MBA, Executive Director and Research Professor at the Tufts Center for the Study of Drug Development, notes:

“Reported benefits include an average 18% cycle time reduction, with standout time savings in areas such as patient monitoring and regulatory documentation preparation.”⁴

Generative AI is proving especially effective for drafting protocols, investigator brochures and clinical study reports with human-in-the-loop quality control - cutting weeks from timelines and improving version control and consistency.

“One company shortened first-draft time from 3 weeks to 3 days, halving writer touch time from 200 to 100 hours”, - reported one McKinsey article.⁵

Operationally, AI-assisted site selection improves the identification of top-performing sites and speeds enrolment, while risk-based monitoring and earlier signal detection reduce rework later. Put together, these changes compound: fewer protocol deviations, faster database locks, cleaner submissions and a clearer path to value.

Predictions & Outcomes: Better Foresight, Safer Bets

Another promising frontier is trial-level prediction. Models that combine drug and target features, prior clinical histories and real-world data are now being used to anticipate approvals, toxicity and phase-transition success. Early evidence on AI-discovered molecules shows markedly higher Phase I success versus historical baselines (80–90% vs historical 40–65%), with Phase II performance roughly in line³ - an encouraging signal that better up-front design and triage may be paying off.

“It is expected that if these trends continue into Phase III and beyond, the pharmaceutical industry could see an increase in the probability of a molecule successfully navigating all clinical phases from 5-10% to 9-18%”, - suggest the review authors.³

EU EHR Interoperability, GxP Validation and MLOps in Pharma: Turning AI into Auditable Impact

Europe is well positioned in regulatory science, CRO capabilities and data-privacy frameworks, yet it still contends with fragmented healthcare data and uneven interoperability across member states. The bar for validation - bias testing, reproducibility, model monitoring - is appropriately high, but burdensome without mature MLOps and documentation.

Collaboration between pharma and tech vendors can be slowed by procurement cycles and integration complexity at sites. The path forward is clear: invest in privacy-preserving data linkage, adopt shared validation playbooks, align sponsor-CRO-site tooling, and build auditable model lifecycles that regulators can interrogate with confidence.

As one review concludes,

“As AI techniques continue to improve and more data become available, it will be important for researchers, clinicians and regulators to collaborate in addressing these challenges. This collaboration will be essential to harness the full potential of AI in predicting the outcomes of clinical trials, enabling us to better manage complex diseases and provide personalised medical treatment to patients”.⁶

Faster Drug Development in Europe - What to Learn at AUTOMA+ 2025

AI is no longer a curiosity in pharma R&D; it is an operational lever. In discovery, it shifts effort in silico and trims months to years from early timelines. In clinical development, it streamlines site selection, patient identification and enrollment, monitoring and regulatory writing, producing broad, double-digit time savings and measurable value. Europe can realise these gains at scale, provided stakeholders move in concert on EHR interoperability, GxP validation and MLOps.

Ready to see what this looks like in practice? Meet peers who are deploying AI across discovery, clinical operations and regulatory at the Pharmaceutical Automation & Digitalisation Congress AUTOMA+ 2025 - compare roadmaps, talk to vendors and leave with implementation tactics you can use on day one.

Get the agenda • Register as a Delegate • Apply to speak • Become an Exhibitor

Sources:

#article

back to the news list

#article